Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RezoluteRZLT +1.10%34 3-Year EBITDA Growth Rate is 19.50% as of Mar. 2026, which is 3% below its 10-year median of 20.00. GuruFocus rates RZLT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, Rezolute ranks better than 55.81% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 33.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rezolute was 52.70% per year. The lowest was -252.80% per year. And the median was 20.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rezolute 3-Year EBITDA Growth Rate Related Terms
RZLT vs QTTB, OCGN, PRLD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Rezolute's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rezolute 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rezolute's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rezolute's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.50% mean?
Rezolute (RZLT) has a 3-Year EBITDA Growth Rate of 19.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rezolute and its competitors. This is near median its historical median of 20.00. According to the industry distribution chart, Rezolute ranks #498 out of 1127 companies in the Biotechnology industry, placing it in the top 44.2%.
Is Rezolute's 3-Year EBITDA Growth Rate too high?
Rezolute's current 3-Year EBITDA Growth Rate of 19.50% is near median its 10-year median of 20.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Rezolute's value of 19.50% is 33.6% above this industry median. Based on the distribution chart, Rezolute ranks #498 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rezolute has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rezolute's 3-Year EBITDA Growth Rate compare to QTTB and OCGN?
According to the Biotechnology industry distribution chart, Rezolute ranks #498 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Rezolute in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Rezolute's value of 19.50% is 33.6% above this benchmark. While the company's 10-year median is 20.00 vs. the industry median of 14.60, Rezolute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rezolute's current 3-Year EBITDA Growth Rate of 19.50% is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rezolute and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rezolute's current 3-Year EBITDA Growth Rate is 19.50%, which is near median its own 10-year median of 20.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rezolute stock overvalued right now?
Rezolute (RZLT) has a current 3-Year EBITDA Growth Rate of 19.50%. The current 3-Year EBITDA Growth Rate is 19.50%, which is near median its 10-year median of 20.00 and 33.6% above the Biotechnology industry median of 14.60. Rezolute's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rezolute (RZLT), the current 3-Year EBITDA Growth Rate is 19.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
34GF Score
Get the complete analysis for RZLT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RZLT has been successfully added to your 
